Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

Second-line treatment for metastatic or locally advanced urothelial cancer (UC) is limited. Immunotherapy is approved as a second-line treatment for metastatic UC. Its use as a first-line agent is limited to patients who are ineligible for cisplatin-based treatments. The fibroblast growth factor rec...

Full description

Bibliographic Details
Main Authors: Teng Li, Wuyun Hu, Lan Jin, Xianghua Yin, Dongxu Kang, Longzhen Piao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
urothelial cancer (UC)
anlotinib
fibroblast growth factor receptor (FGFR)
tislelizumab
PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1164368/full

Similar Items

Similar Items